A Fourth COVID-19 Vaccine, From Novovax, Passed a Key Stage in the Authorization Process

American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot. Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for adults. It’s made with more conventional technology than today’s dominant Pfizer and Moderna shots and the lesser-used Johnson & Johnson option. Novavax shots are already available in Australia, Canada, parts of Europe and multiple other countries, either for initial vaccinations or as mix-and-match boosters. But U.S. clearance is a key hurdle for the Maryland-based company. [time-brightcove not-tgx=”true”] FDA’s vaccine chief Dr. Peter Marks said another choice in the U.S. may entice at least some vaccine holdouts—whatever their reason—to consider rolling up their sleeves. “We do have a problem with vaccine uptake that is very serious in the United States,” Marks said. “Anything we can do to get people more comfortable to accept these potentially life-saving products is something that we feel we are compelled to do.” Read more: Here’s What to Know About COVID-19 Booster Shots for Kids A final FDA decision isn’t expected immediately, as the agency finishes combing through the data. Nor is it clear how widely a Novavax vaccine would be used, at least right aw...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news